Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in Am J Nephrol

Retrieve available abstracts of 23 articles:
HTML format



Single Articles


    March 2021
  1. CHEMOUNY JM, Bobot M, Sannier A, Maisons V, et al
    Kidney Biopsy in Type 2 Diabetes: A Multicenter Cross-Sectional Study.
    Am J Nephrol. 2021 Mar 29:1-10. doi: 10.1159/000514259.
    PubMed     Abstract available


  2. LAZARO-GUEVARA J, Fierro-Morales J, Wright AH, Gunville R, et al
    Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease.
    Am J Nephrol. 2021 Mar 26:1-11. doi: 10.1159/000514578.
    PubMed     Abstract available


    October 2020
  3. LIMONTE CP, Valo E, Montemayor D, Afshinnia F, et al
    A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes.
    Am J Nephrol. 2020 Oct 14:1-10. doi: 10.1159/000510830.
    PubMed     Abstract available


    September 2020
  4. WANG X, Zhang H, Zhang Q, Guan M, et al
    Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Am J Nephrol. 2020 Sep 23:1-9. doi: 10.1159/000510255.
    PubMed     Abstract available


    April 2020
  5. SCHOINA M, Loutradis C, Minopoulou I, Theodorakopoulou M, et al
    Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Diabetic and Non-Diabetic Chronic Kidney Disease.
    Am J Nephrol. 2020 Apr 7:1-10. doi: 10.1159/000507416.
    PubMed     Abstract available


  6. MARATHIAS KP, Lambadiari VA, Markakis KP, Vlahakos VD, et al
    Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Am J Nephrol. 2020 Apr 2:1-8. doi: 10.1159/000507272.
    PubMed     Abstract available


    March 2020
  7. WEIR MR, McCullough PA, Buse JB, Anderson J, et al
    Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
    Am J Nephrol. 2020 Mar 13:1-13. doi: 10.1159/000506533.
    PubMed     Abstract available


    December 2019
  8. JIANG S, Fang J, Yu T, Liu L, et al
    Novel Model Predicts Diabetic Nephropathy in Type 2 Diabetes.
    Am J Nephrol. 2019 Dec 19:1-9. doi: 10.1159/000505145.
    PubMed     Abstract available


  9. CHERNEY DZI, Repetto E, Wheeler DC, Arnold SV, et al
    Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
    Am J Nephrol. 2019 Dec 6:1-9. doi: 10.1159/000504558.
    PubMed     Abstract available


    October 2019
  10. RUILOPE LM, Agarwal R, Anker SD, Bakris GL, et al
    Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Am J Nephrol. 2019 Oct 30:1-12. doi: 10.1159/000503712.
    PubMed     Abstract available


  11. BAKRIS GL, Agarwal R, Anker SD, Pitt B, et al
    Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Am J Nephrol. 2019 Oct 25:1-12. doi: 10.1159/000503713.
    PubMed     Abstract available


    June 2019
  12. COMAI G, Malvi D, Angeletti A, Vasuri F, et al
    Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis.
    Am J Nephrol. 2019 Jun 5:1-8. doi: 10.1159/000500353.
    PubMed     Abstract available


  13. LEE J, Chu C, Guzman D, Fontil V, et al
    Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.
    Am J Nephrol. 2019 Jun 5:1-7. doi: 10.1159/000500706.
    PubMed     Abstract available


    March 2019
  14. WOODS TC, Satou R, Miyata K, Katsurada A, et al
    Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Am J Nephrol. 2019;49:331-342.
    PubMed     Abstract available


  15. BURNS KD, Cherney D
    Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.
    Am J Nephrol. 2019;49:328-330.
    PubMed    


    January 2019
  16. RUGGENENTI P, Remuzzi G
    Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.
    Am J Nephrol. 2019;49:143-145.
    PubMed    


  17. ANYANWAGU U, Donnelly R, Idris I
    Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort.
    Am J Nephrol. 2019;49:146-155.
    PubMed     Abstract available


    May 2018
  18. YAMAMOTO CM, Murakami T, Oakes ML, Mitsuhashi M, et al
    Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus.
    Am J Nephrol. 2018;47:283-291.
    PubMed     Abstract available


    January 2018
  19. CHIN MP, Bakris GL, Block GA, Chertow GM, et al
    Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
    Am J Nephrol. 2018;47:40-47.
    PubMed     Abstract available


  20. TRIEBSWETTER S, Gutjahr-Lengsfeld LJ, Schmidt KR, Drechsler C, et al
    Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes.
    Am J Nephrol. 2018;47:30-39.
    PubMed     Abstract available


    December 2017
  21. JARDINE MJ, Mahaffey KW, Neal B, Agarwal R, et al
    The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Am J Nephrol. 2017;46:462-472.
    PubMed     Abstract available


  22. NEUMILLER JJ, Rhee CM, Kalantar-Zadeh K
    Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
    Am J Nephrol. 2017;46:459-461.
    PubMed    


    September 2017
  23. SAULNIER PJ, Dieter BP, Tanamas SK, McPherson SM, et al
    Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
    Am J Nephrol. 2017;46:276-284.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: